Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for the treatment of type 2 diabetes, have demonstrated pleiotropic effects that may be beneficial in the septic context
J Clin Endocrinol Metab 87: 489-499 Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, et al
Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J (2003) Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up
Treatment recommendations are made on a case-by-case basis following a comprehensive clinical evaluation.
If you have experience with other injectable medications and tolerated them well, you will likely have minimal issues with Retatrutide